TargetMol

Edasalonexent

Product Code:
 
TAR-T15198
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T15198-5mg5mg£304.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15198-50mg50mg£1,163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15198-100mg100mg£1,564.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Edasalonexent is an orally bioavailable inhibitor of NF-κB.
CAS:
1204317-86-1
Formula:
C31H42N2O3
Molecular Weight:
490.688
Pathway:
NF-κb
Purity:
0.98
SMILES:
CCC=C/CC=C/CC=C/CC=C/CC=C/CC=C/CCC(=O)NCCNC(=O)c1ccccc1O
Target:
NF-κB

References

1. Hammers DW, et al. Disease-modifying effects of orally bioavailable NF-?B inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341. 2. Donovan JM, et al. A Novel NF-?B Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 May;57(5):627-639.